If this is an emergency, call 911 or visit the nearest emergency room. Chelsea Urgent Care Chestnut Hill Urgent Care Dedham Urgent Care Quincy Urgent Care Walk-ins are welcome or reserve your spot online. Close Close Alert
References: Procter M, Suter TM, Azambuja E, et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the HERceptin Adjuvant (HERA) trial. Journal of Clinical Oncology [early online publication]. June 7, 2010.
 Morris PG and Hudis CA.Trastuzumab-related cardiotoxicity following anthracycline-based adjuvant chemotherapy: how worried should we be Journal of Clinical Oncology [early online publication]. June 7, 2010.
The exploratory analyses of covariates with information in only a subset of patients suggested that patients with greater shed HER2-ECD level had faster nonlinear clearance (lower Km) (P < 0.001). There was a correlation between shed antigen and SGOT/AST levels; part of the impact of shed antigen on clearance may have been explained by SGOT/AST levels.
The first time you have herceptin you will need to stay in hospital for around 6 hours so you can be monitored for any side effects. For further treatment sessions you'll usually only need up to 2 hours in hospital.
The COVID-19 PHE will expire on May 11, 2023. Effective May 12, 2023, participants seeking admission into a Medicaid Certified bed in a nursing facility that may require a Level II evaluation must complete the Application for Level One Form and Level of Care Assessment online prior to placement. If an individual has an MI, ID, or related condition, a Level II review must be completed by the state mental health authority and/or the contract agent of the state mental health authority prior to admission.
Researchers in the Okayama University Graduate School of Natural Science and Technology have revealed one of resistance mechanisms in breast cancer cells against the antibody drug, trastuzumab (Herceptin).The findings were published online on June 21, 2013 in the journal Journal of Cancer. Trastuzumab is a monoclonal antibody targeted against the HER2 (ErbB2) tyrosine kinase receptor. The efficacy of trastuzumab depends on its ability to induce an immune response. When binding to HER2 (ErbB2), trastuzumab promotes apoptosis in breast cancer cells via antibody-dependent cellular cytotoxicity (ADCC). However, the majority of breast cancer patients with HER2 (ErbB2)-overexpressing tumors develop trastuzumab resistance. Therefore, identifying the molecular mechanisms that contribute to trastuzumab resistance is very important.Professor Seno and his group have shown that caveolin-1 expression in breast cancer cells facilitates ErbB2 endocytosis. When ErbB2 is absorbed into the cell, the attached trastuzumab is also absorbed. As a result, ADCC functions are attenuated. Therefore, caveolin-1 expression in breast cancer cells could be a predictive factor to estimate how cancer cells are likely to respond to trastuzumab treatment.In addition, a novel molecular targeted cancer drug of that efficacy is independent of cavelion-1 expression level has developed successfully as a result of this study.The study was supported by the Japan Society for the Promotion of Science (JSPS) [Kakenhi #24510151,#23650598].Contact Information:Mototaka Senda, Ph.D.US Representative Intellectual Property Office, Organization for Research Promotion and Collaboration, Okayama UniversityFremont, California USATEL: 1-510-797-0907Email: firstname.lastname@example.orgMasaharu Seno, Ph.D.Graduate School of Natural Science and Technology, Okayama University, Okayama Japan
1. Partridge AH, Gelber S, Piccart-Gebhart MJ, et al: Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a Herceptin adjuvant trial. J Clin Oncol. June 10, 2013 (early release online). 59ce067264